Nonviral Gene Therapy of the Nervous System: Electroporation

Ding, Xuefeng; Fan, Ming

doi:10.1007/978-1-4939-3271-9_22

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 A is adapted from ref. 41 . GOF and LOF studies of Sox9 were performed by coelectroporating PBCAG-mSox9-Flag (1.0 μg/μL) and a CRISPR-Cas9 construct with gRNA against Sox9 exon 1 (1.5 μg/μL, gRNA sequence: 5′- GGTGTTCTCCGTGTCCGAGC-3′), respectively.…”

Section: Methodsmentioning

confidence: 99%

Sox9 directs divergent epigenomic states in brain tumor subtypes

Sardar

Chen

Reyes

et al. 2022

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Epigenetic dysregulation is a universal feature of cancer that results in altered patterns of gene expression that drive malignancy. Brain tumors exhibit subtype-specific epigenetic alterations; however, the molecular mechanisms responsible for these diverse epigenetic states remain unclear. Here, we show that the developmental transcription factor Sox9 differentially regulates epigenomic states in high-grade glioma (HGG) and ependymoma (EPN). Using our autochthonous mouse models, we found that Sox9 suppresses HGG growth and expands associated H3K27ac states, while promoting ZFTA-RELA (ZR FUS ) EPN growth and diminishing H3K27ac states. These contrasting roles for Sox9 correspond with protein interactions with histone deacetylating complexes in HGG and an association with the ZR FUS oncofusion in EPN. Mechanistic studies revealed extensive Sox9 and ZR FUS promoter co-occupancy, indicating functional synergy in promoting EPN tumorigenesis. Together, our studies demonstrate how epigenomic states are differentially regulated in distinct subtypes of brain tumors, while revealing divergent roles for Sox9 in HGG and EPN tumorigenesis.

show abstract

Section: Methodsmentioning

confidence: 99%

Sox9 directs divergent epigenomic states in brain tumor subtypes

Sardar

Chen

Reyes

et al. 2022

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…It created temporary pores via electrical pulse in cell membranes through which substances like nucleic acids can pass into cells. Electroporation could almost target all the cells types in vitro , including mammalian cells and bacteria (Ding and Fan, 2016). Electroporation is time saving, labor saving, and cut the cost to a low level.…”

Section: Delivery Methods Of Gene Therapymentioning

confidence: 99%

Current Experimental Studies of Gene Therapy in Parkinson's Disease

Lin

Xie

Zhang

et al. 2017

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson's disease (PD) was characterized by late-onset, progressive dopamine neuron loss and movement disorders. The progresses of PD affected the neural function and integrity. To date, most researches had largely addressed the dopamine replacement therapies, but the appearance of L-dopa-induced dyskinesia hampered the use of the drug. And the mechanism of PD is so complicated that it's hard to solve the problem by just add drugs. Researchers began to focus on the genetic underpinnings of Parkinson's disease, searching for new method that may affect the neurodegeneration processes in it. In this paper, we reviewed current delivery methods used in gene therapies for PD, we also summarized the primary target of the gene therapy in the treatment of PD, such like neurotrophic factor (for regeneration), the synthesis of neurotransmitter (for prolong the duration of L-dopa), and the potential proteins that might be a target to modulate via gene therapy. Finally, we discussed RNA interference therapies used in Parkinson's disease, it might act as a new class of drug. We mainly focus on the efficiency and tooling features of different gene therapies in the treatment of PD.

show abstract